CEO Gregory Flesher (Reneo)
December 9, 2020 08:39 AM ESTUpdated 01:49 PM
Financing

No­vo and Abing­worth back a $95M Se­ries B for Re­neo Phar­ma­ceu­ti­cals, which aims to treat dis­eases of the mi­to­chon­dria

Max Gelman

Senior Editor

Less than two years af­ter its com­ing-out par­ty with a $50 mil­lion launch round, Re­neo Phar­ma­ceu­ti­cals re­turned to the ven­ture well and reeled in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times